GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Genmab offers an alternative route to UltiMab ... CS Vaccine R&D at multinationals, such as Paris-based Sanofi-aventis, GlaxoSmithKline (GSK), Merck and Wyeth, of Madison, New Jersey, continues ...

GSK plc does not currently pay a dividend. AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades ... price-to-book-value ratio and price-to-free-cash-flow ratio.

It offers models for 3D ... that have progressed into clinical trials and improve disease understanding through AI-guided ...

The Nasal Drug Delivery Technology Market is driven by the rising demand for non-invasive administration methods that enhance patient compliance and bioavailability. Innovations such as advanced ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to ...

In partnership with Lyra Health, Starbucks offer personalised, confidential mental health care, free in-person or video ... Pfizer is supporting a Xeljanz trial in Italian COVID-19 patients ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...